135 related articles for article (PubMed ID: 32993564)
41. Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients.
Chen Y; Wu Y; Huang X; Qu P; Li G; Jin T; Xing J; He S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1739-47. PubMed ID: 25702101
[TBL] [Abstract][Full Text] [Related]
42. Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups.
Lin W; Wu S; Chen X; Ye Y; Weng Y; Pan Y; Chen Z; Chen L; Qiu X; Qiu S
Front Oncol; 2020; 10():796. PubMed ID: 32500034
[TBL] [Abstract][Full Text] [Related]
43. Somatic CPEB4 and CPEB1 genes mutations spectrum on the prognostic predictive accuracy in patients with high-grade glioma and their clinical significance.
Boustani MR; Mehrabi F; Yahaghi E; Khoshnood RJ; Shahmohammadi M; Darian EK; Goudarzi PK
J Neurol Sci; 2016 Apr; 363():80-3. PubMed ID: 27000226
[TBL] [Abstract][Full Text] [Related]
44. Ferroptosis in Low-Grade Glioma: A New Marker for Diagnosis and Prognosis.
Liu Y; Xu Z; Jin T; Xu K; Liu M; Xu H
Med Sci Monit; 2020 Jun; 26():e921947. PubMed ID: 32484805
[TBL] [Abstract][Full Text] [Related]
45. TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas.
Han MZ; Xu R; Xu YY; Zhang X; Ni SL; Huang B; Chen AJ; Wei YZ; Wang S; Li WJ; Zhang Q; Li G; Li XG; Wang J
J Exp Clin Cancer Res; 2017 Nov; 36(1):155. PubMed ID: 29110682
[TBL] [Abstract][Full Text] [Related]
46. Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes.
Delic S; Lottmann N; Jetschke K; Reifenberger G; Riemenschneider MJ
Neuropathol Appl Neurobiol; 2012 Apr; 38(2):201-12. PubMed ID: 21722156
[TBL] [Abstract][Full Text] [Related]
47. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.
Sibin MK; Bhat DI; Narasingarao KV; Lavanya Ch; Chetan GK
Tumour Biol; 2015 Sep; 36(10):7607-14. PubMed ID: 25921285
[TBL] [Abstract][Full Text] [Related]
48. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
49. Quantitatively determined survivin expression levels are of prognostic value in human gliomas.
Chakravarti A; Noll E; Black PM; Finkelstein DF; Finkelstein DM; Dyson NJ; Loeffler JS
J Clin Oncol; 2002 Feb; 20(4):1063-8. PubMed ID: 11844831
[TBL] [Abstract][Full Text] [Related]
50. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
51. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
52. Molecular profiles for insular low-grade gliomas with putamen involvement.
Zhou C; Wang Y; Liu X; Liang Y; Fan Z; Jiang T; Wang Y; Wang L
J Neurooncol; 2018 Jul; 138(3):659-666. PubMed ID: 29556911
[TBL] [Abstract][Full Text] [Related]
53. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
Nejo T; Matsushita H; Karasaki T; Nomura M; Saito K; Tanaka S; Takayanagi S; Hana T; Takahashi S; Kitagawa Y; Koike T; Kobayashi Y; Nagae G; Yamamoto S; Ueda H; Tatsuno K; Narita Y; Nagane M; Ueki K; Nishikawa R; Aburatani H; Mukasa A; Saito N; Kakimi K
Cancer Immunol Res; 2019 Jul; 7(7):1148-1161. PubMed ID: 31088845
[TBL] [Abstract][Full Text] [Related]
54. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma.
Guan Y; Chen L; Bao Y; Qiu B; Pang C; Cui R; Wang Y
Int J Clin Exp Pathol; 2015; 8(6):6576-88. PubMed ID: 26261539
[TBL] [Abstract][Full Text] [Related]
55. An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
Ius T; Ciani Y; Ruaro ME; Isola M; Sorrentino M; Bulfoni M; Candotti V; Correcig C; Bourkoula E; Manini I; Pegolo E; Mangoni D; Marzinotto S; Radovic S; Toffoletto B; Caponnetto F; Zanello A; Mariuzzi L; Di Loreto C; Beltrami AP; Piazza S; Skrap M; Cesselli D
Neuro Oncol; 2018 May; 20(6):776-787. PubMed ID: 29228370
[TBL] [Abstract][Full Text] [Related]
56. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts.
Leiss L; Mutlu E; Øyan A; Yan T; Tsinkalovsky O; Sleire L; Petersen K; Rahman MA; Johannessen M; Mitra SS; Jacobsen HK; Talasila KM; Miletic H; Jonassen I; Li X; Brons NH; Kalland KH; Wang J; Enger PØ
BMC Cancer; 2017 Feb; 17(1):108. PubMed ID: 28173797
[TBL] [Abstract][Full Text] [Related]
57. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
58. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
[TBL] [Abstract][Full Text] [Related]
59. Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis.
Kong Y; Feng ZC; Zhang YL; Liu XF; Ma Y; Zhao ZM; Huang B; Chen AJ; Zhang D; Thorsen F; Wang J; Yang N; Li XG
Front Immunol; 2020; 11():1281. PubMed ID: 32765489
[No Abstract] [Full Text] [Related]
60. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
